Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
25.34(c) 24.98(c) 24.96(c) 25.4(c) 25.74 Last
417 601 541 780 367 376 386 218 585 780 Volume
+0.76% -1.42% -0.08% +1.76% +1.34% Change
More quotes
Financials
Sales 2020 475 M 568 M 568 M
Net income 2020 26,4 M 31,6 M 31,6 M
Net cash position 2020 7,50 M 8,96 M 8,96 M
P/E ratio 2020 177x
Yield 2020 -
Sales 2021 549 M 656 M 656 M
Net income 2021 44,6 M 53,3 M 53,3 M
Net cash position 2021 68,5 M 81,9 M 81,9 M
P/E ratio 2021 89,5x
Yield 2021 -
Capitalization 4 202 M 5 024 M 5 022 M
EV / Sales 2020 8,83x
EV / Sales 2021 7,53x
Nbr of Employees 3 444
Free-Float 90,7%
More Financials
Company
Evotec SE specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment; - other: target identification, pharmacological tests development, broadband screening... 
Sector
Biotechnology & Medical Research
Calendar
12/02 | 04:00pmPräsentation
More about the company
Notations Surperformance© of Evotec SE
Trading Rating : Investor Rating :
More Ratings
All news about EVOTEC SE
11/25EVOTEC : and Rappta Therapeutics enter discovery and development partnership foc..
AQ
11/24EVOTEC : And rappta therapeutics enter discovery and development partnership foc..
EQ
11/20EVOTEC : presents growth drivers of 'Autobahn to Cures' at Capital Markets Day
AQ
11/20EVOTEC : Gets a Buy rating from RBC
MD
11/19EVOTEC : Presents growth drivers of 'autobahn to cures' at capital markets day
EQ
11/18EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..
AQ
11/17EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..
PU
11/17EVOTEC : And storm therapeutics leverage indigo platform to progress oncology pr..
EQ
11/16EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
11/13EVOTEC : Deutsche Bank reiterates its Buy rating
MD
11/13EVOTEC : expands Oxfordshire site into a fully-integrated R&D centre named 'Doro..
AQ
11/12EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
11/12EVOTEC : Receives a Buy rating from Baader Bank
MD
11/12EVOTEC : RBC keeps its Buy rating
MD
11/12EVOTEC : expands Oxfordshire site into a fully-integrated R&D centre named "Doro..
PU
More news
News in other languages on EVOTEC SE
11/24EVOTEC : Und rappta therapeutics gehen auf onkologie-target fokussierte forschun..
11/24Evotec und rappta therapeutics gehen auf onkologie-target fokussierte forschu..
11/20EVOTEC : RBC à l'achat
11/20RBC hebt Ziel für Evotec auf 32 Euro - 'Outperform'
11/19EVOTEC : präsentiert Wachstumstreiber der "Autobahn to Cures" auf dem Capital Ma..
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Stock Trading Strategies
EVOTEC SE - 07/24
Back on price levels to sell
SELL
More Stock Trading Analysis
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 30,67 €
Last Close Price 25,40 €
Spread / Highest target 41,7%
Spread / Average Target 20,7%
Spread / Lowest Target 10,2%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE10.20%4 937
LONZA GROUP AG55.15%44 901
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 811
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832